| 1.95 0 (0%) | 12-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.66  |
1-year : | 4.28 |
| Resists | First : | 3.14 |
Second : | 3.66 |
| Pivot price | 2.72  |
|||
| Supports | First : | 2.46 |
Second : | 2.03 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.78 |
| MA(100) : | 2.77 |
MA(250) : | 3.95 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.3 |
D(3) : | 53.8 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 6.15 | Low : | 1.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FWP ] has closed above bottom band by 33.5%. Bollinger Bands are 6.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.6 - 2.61 | 2.61 - 2.63 |
| Low: | 2.57 - 2.58 | 2.58 - 2.6 |
| Close: | 2.58 - 2.6 | 2.6 - 2.62 |
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0.82 |
| EPS Est This Year | 2.49 |
| EPS Est Next Year | -0.1 |
| Book Value (p.s.) | 8.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -3.5 % |
| Return on Equity (ttm) | -0.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -9.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -76.49 |
| Dividend | 160.66 |
| Forward Dividend | 0 |
| Dividend Yield | 6179.6% |
| Dividend Pay Date | 2019-12-05 |
| Ex-Dividend Date | 2017-09-11 |
|
|
|
|
|
|
|
|
|